The recombinant zoster vaccine (Shingrix) was associated with a 17% increase in time without a dementia diagnosis, compared with the live vaccine. This translated into 164 additional days without a ...

Evidence from a team of scientists at the University of Oxford indicates that the newer shingles vaccine is more protective against dementia compared to the previous shingles vaccine. Both shingles ...

If you're over age 50 or have a suppressed immune system, you may have heard your doctor recommend the shingles vaccine. But ...

Recombinant protein vaccines, which are obtained by conventional genetic engineering, are based on the proteins of target pathogens that can activate our immune systems. Unlike other types of vaccines ...

A study by researchers in Texas describes a mouse model in which a subunit vaccine with alum-CpG adjuvant was tested for its ability to induce a broadly neutralizing antibody response against the ...

Receipt of a newer recombinant version of a shingles vaccine is associated with a significant delay in dementia diagnosis in older adults, a new study suggests. The study builds on previous ...

In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy of ...

RZV offers substantial clinical and economic benefits but has low uptake among adults aged 50 and older compared to other vaccines. By 2020, only 10.8% of adults aged 50 and older had completed both ...

A type of herpes virus — the varicella-zoster virus — causes chickenpox in childhood and shingles later in life. Shingles travels along nerves, triggering a distinctive blistering rash and what some ...

A potential vaccine against the deadly Nipah virus has shown encouraging safety and immune responses in an early human trial, ...